Mironid
Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.
Contact Mironid via their website
News archive
01/11/2019 Meet Mironid at BIO-Europe and Kidney Week this month...more
18/06/2019 Mironid publishes in PNAS: new approach for ADPKD treatment...more
12/04/2019 Mironid® secures Innovate UK Biomedical Catalyst Grant...more
13/03/2019 Meet Mironid at Bio-Europe Spring, Vienna 24-27 March...more
08/02/2019 New Mironid publication on PDE4D7 and prostate cancer...more
28/03/2018 Prof Dorien Peters joins Mironid's SAB...more
28/03/2018 Mironid announces appointment of Dr Steve Felstead as Chief Medical Officer...more
19/12/2017 Mironid published in European Urology...more
27/09/2017 Team Mironid to support PKD awareness in the Great Scottish Run...more
11/05/2017 Mironid CSO published in Journal of Clinical Investigation (JCI)...more
07/03/2017 Mironid will be attending Bio Europe Spring in Barcelona...more
06/02/2017 Mironid co-founders publish in The Biochemical Journal...more
01/02/2017 Sygnature Discovery, Mironid, and Peak Proteins to collaborate...more
30/01/2017 Mironid announces Early Stage Award from Innovate UK’s Biomedical Catalyst...more
05/01/2017 Mironid COO, Neil Wilkie, is attending JPM and Biotech Showcase conferences...more
05/01/2017 Dr George Muller joins Mironid's Scientific Advisory Board...more
12/12/2016 Mironid and University of Sheffield Announce Collaboration on ADPKD Drug Discovery...more
08/12/2016 Prof Albert Ong has joined Mironid's Scientific Advisory Board...more
07/12/2016 Mironid has appointed Dr Peter Webborn as DMPK consultant...more
24/11/2016 Read Mironid's Blog Post for Global Entrepreneurship Week - Scotland...more
17/11/2016 Mironid joins the BioPartner programme...more
